The CIS insulin market was valued at USD 3.05 billion in 2023 and is anticipated to reach USD 4.67 billion by 2030, growing at a CAGR of 5.6% from 2024 to 2030. The market growth is primarily driven by the rising prevalence of diabetes, lifestyle changes leading to obesity, and the growing awareness regarding effective diabetes management. Increasing investments in research and development, coupled with continuous advancements in insulin formulations and delivery technologies, are further accelerating market expansion. The demand for insulin has also been fueled by the increasing incidence of both type I and type II diabetes, as modern lifestyles and aging populations contribute to a higher disease burden across the region.

The growing number of diabetic patients remains one of the key factors boosting market growth across the CIS region. According to the International Diabetes Federation, the number of adults with diabetes in Europe is projected to increase from 59 million in 2021 to 62 million by 2030, reflecting a steady rise in demand for insulin therapies. Technological innovations in insulin production and delivery such as advanced insulin analogs, biosimilars, and digital insulin management tools have significantly improved patient outcomes. For example, Novo Nordisk’s ultra-long-acting insulin analog, Tresiba, introduced in 2024 in the CIS market, provides enhanced glycemic control with reduced risk of hypoglycemia, offering patients improved treatment safety and flexibility.

Key Market Trends & Insights:

• Based on product, the long-acting insulin segment dominated the market with a 52.7% share in 2023, as it offers improved dosage flexibility and convenience for patients. The biosimilars segment is expected to register the fastest CAGR of 15.3% during the forecast period, driven by cost-effectiveness and growing government support for affordable healthcare.
• By type, the insulin analog segment held the largest revenue share of 89.0% in 2023, owing to its superior pharmacokinetic properties and ability to mimic natural insulin action. The human insulin segment is expected to grow steadily as a more economical treatment option.
• Based on application, the type 1 diabetes segment accounted for a dominant 79.6% market share in 2023, given its complete dependency on insulin therapy. However, the type 2 diabetes segment is projected to grow at the fastest CAGR of 11.6% as awareness and diagnosis rates improve.
• By distribution channel, retail and specialty pharmacies captured 89.4% of market revenue in 2023, supported by convenient access and the availability of multiple insulin variants. Meanwhile, hospital pharmacies are projected to witness notable growth due to the rising number of in-patient diabetes treatments and surgeries.

Order a free sample PDF of the CIS Insulin Market Intelligence Study, published by Grand View Research.

Key Companies & Market Share Insights:

Leading insulin manufacturers in the CIS region are focusing on product innovation, mergers and acquisitions, and regional partnerships to strengthen their market position. The introduction of biosimilar insulin has opened the market to new entrants, increasing competition and affordability. Governments across the CIS region are promoting local insulin production and attracting global pharmaceutical firms to establish manufacturing facilities, thereby reducing dependency on imports.

Novo Nordisk A/S continues to lead with its advanced diabetes care solutions, including innovative insulin delivery systems and treatments addressing various hormonal disorders. Eli Lilly and Company also plays a major role, leveraging biotechnology and genetic medicine to develop next-generation therapies that enhance patient care. Continuous R&D investments, coupled with a growing focus on personalized medicine, are expected to shape the future of the CIS insulin market.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

In conclusion, the CIS insulin market is poised for steady growth, driven by the rising prevalence of diabetes, growing awareness about effective disease management, and continuous technological advancements in insulin formulations and delivery systems. The introduction of biosimilars and next-generation insulin analogs is improving accessibility and affordability, benefiting both healthcare systems and patients. Government initiatives supporting local production and multinational partnerships are further strengthening the regional market landscape. Additionally, increasing investments in research and development are expected to foster innovation and enhance treatment efficiency. Overall, the CIS insulin market is on a strong upward trajectory, supported by evolving healthcare infrastructure and a growing focus on patient-centric diabetes care solutions.